Close Menu

NEW YORK – Seattle Genetics said on Thursday that the new drug application for its investigational agent tucatinib has been accepted by the US Food and Drug Administration.

The NDA is for the use of tucatinib in combination with chemotherapies capecitabine and trastuzumab (Genentech's Herceptin) to treat patients with locally advanced, unresectable, or metastatic HER2-positive breast cancer who have received at least three prior HER2-targeted therapies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.